Risk of Stagnation in Sales, Production, and Research and Development Due to COVID-19
First written in FY2020. 4 of 9 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2023MitigatedAnnual report
「The spread of COVID-19 is currently subsiding, and countries are moving ahead with easing restrictions on activities.」
The status of the subsiding spread of COVID-19 and the easing of restrictions on activities is described, indicating that the risk posed by the external environment is declining. However, the risk of stagnation in activities if the infection spreads again or persists remains. - FY2023-Q3RestatedAnnual report
「During the nine-month period ended in the third quarter, there was no new business risk or material change in the business risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material change in the risk of stagnation in sales, production and research and development activities due to COVID-19. - FY2022RestatedAnnual report
「There was no impact on results for the consolidated fiscal year due to the spread of COVID-19.」
The company reconfirmed that there was no impact on results for the consolidated fiscal year while maintaining the risk of stagnation in sales, production and research and development activities due to COVID-19. - FY2022-Q3RestatedAnnual report
「There was no impact on results during the cumulative third-quarter consolidated period due to the spread of COVID-19.」
The company reconfirmed that COVID-19 had no impact on results during the cumulative third-quarter consolidated period. - FY2022-Q2No impact on results for the current quarterAnnual report
「There was no impact on results during the cumulative second-quarter consolidated period due to the spread of COVID-19.」
The company states that COVID-19 had no impact on results during the cumulative second-quarter consolidated period. - FY2022-Q1No impact on results for the current quarterAnnual report
「There was no impact on results during the cumulative first-quarter consolidated period due to the spread of COVID-19.」
The company states that COVID-19 had no impact on results during the cumulative first-quarter consolidated period. The risk of stagnation in activities due to further spread or a prolonged course of the infection remains disclosed. - FY2021-Q3RestatedAnnual report
「There was no impact on results during the cumulative third-quarter consolidated period due to the spread of COVID-19.」
The company reconfirmed that COVID-19 had no impact on results during the cumulative third-quarter consolidated period. However, the risk of stagnation in activities due to further spread or a prolonged course of the infection remains disclosed. - FY2021-Q1No impact on results for the current quarterAnnual report
「There was no impact on results during the cumulative first-quarter consolidated period due to the spread of COVID-19.」
The company states that COVID-19 had no impact on results during the cumulative first-quarter consolidated period. However, the risk of stagnation in sales, production and research and development activities due to further spread or a prolonged course of the infection remains. - FY2020First statedAnnual report
「However, if further spread or a prolonged course of the infection results in illness among the company's officers or employees, or has a significant impact on its business partners or external contractors, the resulting stagnation of sales, production and research and development activities could have a significant impact on the company's financial position and operating results.」
The impact of the spread and prolonged course of COVID-19 on officers and employees, business partners and external contractors has been disclosed as a new business continuity risk. The company also states that there was no impact on results for the consolidated fiscal year.